Table 1. Correlation between the expression of p-NF-κB and clinicopathological parameters in melanoma patients.
| Characteristics | p-NF-κB expression | P value | ||||
|---|---|---|---|---|---|---|
| − | + | ++ | +++ | |||
| Age | ||||||
| <50 | 8 (19.5%) | 12 (29.3%) | 10 (24.4%) | 11 (26.8%) | 0.609 | |
| ≥50 | 2 (8.0%) | 8 (32.0%) | 6 (24.0%) | 9 (36.0%) | ||
| Gender | ||||||
| Male | 3 (10.0%) | 6 (20.0%) | 11 (36.7%) | 10 (33.3%) | 0.087 | |
| Female | 7 (19.4%) | 14 (38.9%) | 5 (13.9%) | 10 (27.8%) | ||
| Ulcer history | ||||||
| Yes | 8 (20.0%) | 11 (27.5%) | 9 (22.5%) | 12 (30.0%) | 0.579 | |
| No | 2 (7.7%) | 9 (34.6%) | 7 (26.9%) | 8 (30.8%) | ||
| Position | ||||||
| Limbs | 8 (17.8%) | 11 (24.4%) | 12 (26.7%) | 14 (31.1%) | 0.454 | |
| Truncus | 2 (9.5%) | 9 (42.9%) | 4 (19.0%) | 6 (28.6%) | ||
| Clinical stage | ||||||
| I-II | 7 (21.9%) | 9 (28.1%) | 11 (34.4%) | 5 (15.6%) | 0.029* | |
| III-IV | 3 (8.8%) | 11 (32.4%) | 5 (14.7%) | 15 (44.1%) | ||
| Clark level | ||||||
| I-IV | 7 (21.2%) | 10 (30.3%) | 8 (24.2%) | 8 (24.2%) | 0.494 | |
| V | 3 (9.1%) | 10 (30.3%) | 8 (24.2%) | 12 (36.4%) | ||
| Breslow thickness | ||||||
| <4mm | 6 (18.2%) | 13 (39.4%) | 5 (15.2%) | 9 (27.3%) | 0.199 | |
| ≥4mm | 4 (12.1%) | 7 (21.2%) | 11 (33.3%) | 11 (33.3%) | ||
*
P<0.05